NCT02566668Completed
Immune Interactions in Severe Asthma
Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma
Source: ClinicalTrials.gov · Last updated 9 Jan 2025
Brief summary (registry, in English)
This research study is being done to learn more about severe asthma by comparing people with severe asthma to those with milder forms of asthma and people without asthma, at baseline and over time. Individuals are being asked to join a research study to help understand the differences in the lungs and blood of participants with severe asthma compared to those with milder asthma and healthy individuals, as well as differences in overall health. Investigators also want to determine whether these differences predict asthma-related and biologic outcomes over 1 year of follow up.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 115 (actual)
- First submitted
- 18 Sept 2015
- Start date
- Sept 2015
- Primary completion date
- 22 Sept 2022
- Lead sponsor
- University of Pittsburgh
- Diseases
- Asthma
- NCT number
- NCT02566668
What you commit to
- Study type: Observational
- Participants enrolled: 115
- From Sept 2015 to the primary completion date, 22 Sept 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Vocal cord dysfunction, cystic fibrosis or chronic obstructive pulmonary disorder
- Other lung disease, or any coronary artery disease, hypertension, diabetes or renal failure that is not well-controlled.
- Healthy Controls only: Pre-bronchodilator FEV1/Forced vital capacity (FVC) <0.70 or an improvement in FEV1 of more than 12% following 4 puffs of albuterol.
Other
- Greater than 10 pack year smoking history (none in the last year)
Who the study is looking for
- 18-65 years of age
- Non-smoker
- Asthmatic subjects must also demonstrate forced expiratory volume in 1 second (FEV1) bronchodilator reversibility ≥12% or airway hyperresponsiveness reflected by a methacholine provocative concentration causing a 20% fall in FEV1 (PC20) ≤16 mg/mL (Historical methacholine data from previous National Institutes of Health (NIH) trial will be allowed)
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Asthma Institute at UPMC Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.